Financial Data and Key Metrics Changes - InMode generated revenues of $95.6 million in Q2 2025, compared to $86.4 million in Q2 2024, which excluded $16.2 million in preorders for new platforms not delivered by 2024 [7][8] - GAAP net income increased to $26.7 million, up 12% from $23.8 million in the previous year, while non-GAAP net income rose to $30.1 million from $29 million [11] - GAAP diluted earnings per share (EPS) for Q2 were $0.42, significantly up from $0.28 in 2024, and non-GAAP diluted EPS was $0.47, up from $0.34 [11] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 84% of total revenues in Q2 2025 [7] - Sales outside the U.S. reached $45 million, representing 48% of overall sales, marking an 11% year-over-year increase [8] - Sales and marketing expenses increased to $47.5 million from $45.1 million in the same period last year, reflecting continued investment in the sales team [9] Market Data and Key Metrics Changes - Europe was the largest geographical revenue contributor, achieving a record of $23 million [8] - The company has a direct sales force of over 297 representatives and distributor coverage in more than 74 countries [9] Company Strategy and Development Direction - The company is restructuring its sales team to enhance market penetration, particularly in the ophthalmology market with a specialized manager and dedicated sales team for the Envision platforms [5] - InMode is expanding its global footprint with new direct operations in Thailand and Argentina to improve customer support and streamline operations [5] - A user meeting is scheduled for late August to launch new wellness platforms aimed at increased blood circulation and pain relief for the urology community, with initial revenue expected in Q4 [6] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging medical aesthetic market, particularly in North America, due to reduced personnel spending and fewer treatments [4][5] - The company remains confident in its offerings and brand recognition, supported by a strong balance sheet and diversified portfolio [6] - Management expects revenues for 2025 to be between $365 million and $375 million, down from previous guidance of $395 million to $405 million [12][13] Other Important Information - Gross margin remained strong at 80% on a GAAP basis, consistent with Q2 2024, while non-GAAP gross margin was 80%, down from 81% [8][9] - The company generated $24 million in cash from operating activities during the quarter [11] - The impact of U.S. tariffs is expected to reduce gross margins by approximately 2% to 3% [12] Q&A Session Summary Question: Dynamics in Q1 and Q2 - Management noted that both Q1 and Q2 results were below expectations, with a slight weakness observed in both quarters [19][23] Question: Capital Purchases and Business Investment - Management indicated that there was no significant change in purchasing behavior between Q1 and Q2, with the market remaining challenging [23] Question: Capital Allocation and Share Repurchase - The company is considering additional share buybacks and remains open to various capital allocation options, but currently has no acquisitions planned [34] Question: Non-Invasive Procedure Growth - The increase in non-invasive procedures is attributed to customer behavior and the introduction of new platforms like Optimus Max [37] Question: Tariff Impact - The original tariff rate was reduced from 17% to 10% temporarily, with an expected annual impact of 2% to 3% on gross margins [63][66] Question: Urology Market and FDA Approval - The company is developing a platform for erectile dysfunction but is currently limited to pilot testing for blood circulation and pain relief until FDA approval is obtained [48][72] Question: Growth in International Markets - Management expressed confidence in the sustainability of growth in international markets, particularly in Europe, as the company expands its global presence [75]

Financial Data and Key Metrics Changes - The company reported a revenue of $78.1 million for the first quarter, a decrease of 7.6% compared to the previous year [8] - Gross margin fell to 34.1% from 36.9% in the previous quarter, attributed to a transition phase in production [8][10] - The company experienced an operating loss of €800,000 for the quarter, with net financial costs increasing to $2.9 million from $2.2 million due to currency volatility [10] Business Line Data and Key Metrics Changes - The transition of Natuzzi Edition production from China to Italy impacted gross margins, leading to a temporary decrease in profitability [9][10] - Significant investments of approximately $2 million were made primarily on factory improvements during the quarter [10] Market Data and Key Metrics Changes - Consumer confidence in the US has declined to levels not seen since early 2023, with European confidence down by 3.1 percentage points [11] - The market environment remains challenging, with consumers postponing durable purchases [12] Company Strategy and Development Direction - The company is focusing on enhancing its brand commercial strategy, integrating collection, marketing, and customer experience [16] - Natuzzi plans to strengthen its retail and wholesale channels, with a particular emphasis on the North American market [21] - The company is exploring sustainable production locations for Natuzzi Editions to mitigate tariff impacts [33] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the difficult business environment, exacerbated by US trade duties and geopolitical tensions [16] - The company is committed to protecting margins and is actively reviewing pricing strategies in response to tariffs [33][36] - There is a focus on improving operational efficiency and brand strength to deliver sustainable value to stakeholders [24] Other Important Information - The company has returned to the Salon del Mobile Fair in Milan, unveiling new collections that reflect its evolution as a global lifestyle brand [17] - The introduction of a new software platform for retail performance assessment is showing early signs of improvement [45] Q&A Session Summary Question: Impact of production shift on gross margin - The production shift from China to Italy has caused disruptions, leading to a decrease in gross margin [31] Question: Future gross margin expectations - Management is reviewing pricing strategies and production allocations to protect margins, but specific guidance on future margins was not provided [36] Question: Sustainability of operating expenses - Operating expenses were reduced to $27.4 million, and management expressed confidence in maintaining this level with ongoing cost reviews [39] Question: Early signs of improvement in retail technology - The new performance assessment platform is enabling data-driven decisions and improving store performance [45] Question: Potential of the commercial division - The trade and contract division is seeing growth, with a focus on B2B relationships and bespoke solutions for hospitality and residential sectors [62]